ArticleBMC gastroenterology2010
The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients.
Article in BMC gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Psychometric validation of the SF-36Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2018Pooled it
- The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.Digestive diseases and sciences · 2015Pooled it
- Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2019Trial
- Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.Clinical and experimental immunology · 2015Trial
- Effects of comprehensive intervention on health-related quality of life in patients with chronic hepatitis B in China.BMC health services research · 2013Trial
- Disability among Palestinian patients with inflammatory bowel disease: evaluation using the IBD Disk and identification of associated factors.Crohn's & colitis 360 · 2026Article
- "I Probably Am Being a Naughty Boy, But…" Reasons for Non-Adherence to Prescribed Medication, as Perceived by People Living with Inflammatory Bowel Disease: A Qualitative Study.Patient preference and adherence · 2025Article
- Can we change the natural course of inflammatory bowel disease?Therapeutic advances in gastroenterology · 2023Review
- Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment.International journal of environmental research and public health · 2021Review
- Article
- Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort.Medicine · 2015Observational
- Use of thiopurines in inflammatory bowel disease: Safety issues.World journal of gastrointestinal pharmacology and therapeutics · 2014Review
- Inflammatory bowel disease unclassified.Journal of Zhejiang University. Science. B · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with IBD treated with thiopurines and assess the short- and long-term impacts of the treatment on HRQoL.
methodsNinety-two consecutive patients who started treatment with thiopurines were prospectively included. Evaluation of HRQoL was performed at months 0, 6, and 12 using two questionnaires, the Short-Form Health Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ).
resultsBaseline score of IBDQ was 4,6, range (2,31-6,84), with an impairment of the five dimensions of HRQoL compared with inactive patients. Results obtained in 8 dimensions of SF-36 showed worse HRQoL than Spanish general population. At 6 months patients had a significant improvement in overall IBDQ score -5,8 (1,58 -6,97)- and also in all IBDQ dimensions. All the 8 dimensions of SF-36 obtained a significant improvement. At twelve months score of IBDQ was 6,1, range (2,7-6,98), with improvement in all dimensions compared with baseline and 6 months. SF-36 showed a similar significant improvement in all subscales.
conclusionsThiopurine immunomodulators alone or with other treatments have a positive and long lasting impact on HRQoL of IBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.